MaaT013

MaaT013, a microbiome therapy, showed promising results as a third-line treatment for GI-aGvHD, with a 62% GI-ORR at 28 days, surpassing the expected 38%. It achieved 38% CR and 20% VGPR, with a 54% 12-month OS rate. The therapy targets the gut-immune interface, offering new hope for patients.

The phase 3 ARES study demonstrated MaaT013's efficacy in treating acute graft-versus-host disease with gastrointestinal involvement, achieving a 62% GI-overall response rate, including 38% complete response. The 12-month overall survival rate was 54%, with responders at day 28 showing a 67% survival rate. MaaT013, a microbiome therapy, offers a promising third-line treatment option for patients resistant to steroids or ruxolitinib.

MaaT Pharma's Phase III ARES trial showed MaaT013, a microbiome-based therapy for graft-versus-host disease, achieved a 62% gastrointestinal response rate and a 54% 12-month survival probability. The therapy, aiming for European regulatory submission by mid-2025, restores immune-gut microbiome balance using a diverse microbial mix.

MaaT013 demonstrated a 62% gastrointestinal overall response rate at Day 28 in a Phase 3 trial for third-line GI-aGvHD treatment, surpassing the expected 38%. It showed a 54% 1-year survival probability, with plans for European MAA submission by mid-2025. MaaT Pharma aims to redefine GI-aGvHD management.

MaaT013's Phase III trial marks a significant breakthrough in third-line GI-aGvHD treatment, targeting the gut-immune interface to potentially transform disease management. Concurrently, Microbiotica advances in microbiome therapy with MB097's Phase Ib trial for melanoma.

MaaT Pharma's stock surged over 19% on the Paris Bourse after its Phase 3 trial for MaaT013 in aGvH showed a 62% gastrointestinal response rate, exceeding expectations. Analysts raised the success probability to 95% and the price target to 22 euros, with a marketing application expected by mid-2025.

MaaT Pharma's Phase III trial of MaaT013 for GI-aGvHD met primary endpoints with a 62% GI-ORR, surpassing the expected 38%. The therapy, aimed at severe dysbiosis, led to a 14.71% stock increase. It's seen as a breakthrough for third-line GI-aGvHD treatment, offering new hope for patients unresponsive to steroids and ruxolitinib.

MaaT Pharma SA (MAAT.PA) stock rose 13.22% to €9.08, with a market cap of €127.932M. The company develops gut microbiome therapies for cancer, including MaaT013 (phase 3 for graft vs. host disease), MaaT033 (phase 2b for leukemia), and MaaT03X (solid tumors). Based in Lyon, France, it was founded in 2014.

MaaT Pharma's MaaT013, a microbiome therapy for acute graft-versus-host disease (aGvHD) with gastrointestinal involvement, showed promising results in a phase 3 trial. 62% of patients responded, with 38% achieving complete gastrointestinal response. The therapy targets the gut-immune interface, offering new hope for patients resistant to existing treatments. MaaT plans EU approval filing and is developing MaaT033 for cancer patients.